PETRI DISH PERSPECTIVES

EXPLORE

Society & Culture

© 2024 PodJoint

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/b4/0d/3c/b40d3cd1-92a9-98e5-ef8d-bad6fcc4e42a/mza_2004739456060853069.jpg/600x600bb.jpg

PETRI DISH PERSPECTIVES

Manead Khin

30 episodes

4 days ago

Send us a text In this episode of Petri Dish Perspectives:, we dive into one of the most dramatic biotech stories of the decade: the rise of Metsera, the VC-backed obesity startup that triggered a rare billion-dollar bidding war between two pharma giants, Pfizer and Novo Nordisk. We explore how Metsera quietly emerged from Flagship’s venture creation engine, how its science positioned it as a next-generation competitor in the GLP-1 era, and why its pipeline, from injectable GLP-1s to amylin a...

Show more...

Health & Fitness,

All content for PETRI DISH PERSPECTIVES is the property of Manead Khin and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Send us a text In this episode of Petri Dish Perspectives:, we dive into one of the most dramatic biotech stories of the decade: the rise of Metsera, the VC-backed obesity startup that triggered a rare billion-dollar bidding war between two pharma giants, Pfizer and Novo Nordisk. We explore how Metsera quietly emerged from Flagship’s venture creation engine, how its science positioned it as a next-generation competitor in the GLP-1 era, and why its pipeline, from injectable GLP-1s to amylin a...

Show more...

Health & Fitness,

Episodes (20/30)

PETRI DISH PERSPECTIVES

Episode 30: Metsera

Send us a text In this episode of Petri Dish Perspectives:, we dive into one of the most dramatic biotech stories of the decade: the rise of Metsera, the VC-backed obesity startup that triggered a rare billion-dollar bidding war between two pharma giants, Pfizer and Novo Nordisk. We explore how Metsera quietly emerged from Flagship’s venture creation engine, how its science positioned it as a next-generation competitor in the GLP-1 era, and why its pipeline, from injectable GLP-1s to amylin a...

4 days ago

25 minutes

PETRI DISH PERSPECTIVES

Episode 29: Charles River Laboratories

Send us a text In this episode of Petri Dish Perspectives, we dive into the untold story of Charles River Laboratories, the quiet giant behind nearly every major drug you’ve ever heard of. From its origins on the banks of Massachusetts’ Charles River, where Dr. Henry Foster began breeding lab rats to support post-war research, to its evolution into a global scientific infrastructure company, Charles River has shaped the very foundation of modern drug development. We’ll explore how a small ani...

1 week ago

23 minutes

PETRI DISH PERSPECTIVES

Episode 28: Regeneron

Send us a text In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead dives into the remarkable story of Regeneron Pharmaceuticals, from its humble beginnings in Tarrytown to becoming one of the world’s leading biotech innovators. Discover how founders Leonard Schleifer and George Yancopoulos turned early failure into scientific triumph with breakthrough drugs like Eylea, Dupixent, and the COVID-19 antibody cocktail that changed the global response. We explore how Regenero...

2 weeks ago

23 minutes

PETRI DISH PERSPECTIVES

Episode 27: Tempus AI

Send us a text What if the cure for cancer or the key to mental health, wasn’t hidden in a new drug, but in data itself? In this episode of Petri Dish Perspectives, we uncover the story of Tempus AI, the company turning raw medical information into lifesaving insight. Founded by Eric Lefkofsky, the entrepreneur behind Groupon, Tempus began as a deeply personal mission to bring clarity to cancer care. Today, it’s one of the most advanced AI-driven healthcare platforms in the world, combining g...

3 weeks ago

23 minutes

PETRI DISH PERSPECTIVES

Episode 26: Wuxi AppTec

Send us a text What if the secret engine driving modern drug discovery wasn’t in Boston or Basel, but in Shanghai? In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead dives deep into the rise of WuXi AppTec, a company that redefined how the world develops medicine. We explore its fascinating journey, from a humble chemistry startup founded by Dr. Ge Li to a global R&D and manufacturing giant that helps nearly every top pharma and biotech company bring therapies to l...

1 month ago

23 minutes

PETRI DISH PERSPECTIVES

Episode 25: CVS Health

Send us a text From a small pharmacy in Massachusetts to a $100 billion healthcare empire, CVS Health has redefined what it means to be a pharmacy. In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead dives into CVS’s fascinating evolution, from its early days as Consumer Value Store to its bold moves acquiring Aetna and transforming into a fully integrated healthcare provider. We explore how CVS blended retail, insurance, and clinical services to build one of the most p...

1 month ago

23 minutes

PETRI DISH PERSPECTIVES

Episode 24: GLP-1 Agonists

Send us a text From a lizard’s venom to Hollywood’s favorite weight-loss trend, this episode of Petri Dish Perspectives: Biotech Unleashed dives deep into the fascinating journey of GLP-1 agonists. Discover how scientists uncovered a gut hormone that revolutionized diabetes care, led to the creation of Ozempic and Mounjaro, and sparked a cultural movement around body image and health. We’ll trace the science, the breakthroughs, and the billion-dollar race shaping the future of metabolic...

1 month ago

23 minutes

PETRI DISH PERSPECTIVES

Episode 23: Alnylam

Send us a text What if you could silence disease at its genetic root? That was the bold promise behind RNA interference (RNAi), one of the most groundbreaking scientific discoveries of the 21st century. In this episode, we dive into the story of Alnylam Pharmaceuticals, from its founding by a powerhouse team of Nobel laureates, pioneering scientists, and biotech visionaries, to its transformation into the world’s first RNAi therapeutics company. We explore the challenges of turning a fragile ...

1 month ago

23 minutes

PETRI DISH PERSPECTIVES

Episode 22: Takeda

Send us a text From its humble beginnings in 1781 as a family-run herbal medicine shop in Osaka to becoming one of the world’s top 10 pharmaceutical companies, Takeda’s story is one of resilience, reinvention, and bold transformation. In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead unpacks Takeda’s 240-year journey, from the vision of founder Chobei Takeda, through the blockbuster eras of Prevacid and Actos, to the game-changing acquisition of Shire under CEO Christ...

2 months ago

24 minutes

PETRI DISH PERSPECTIVES

Episode 21: Moderna

Send us a text From secrecy and skepticism to one of the fastest vaccine rollouts in history, this episode of Petri Dish Perspectives: Biotech Unleashed dives into the remarkable journey of Moderna. We trace the company’s early hype, billion-dollar partnerships, and criticism for overpromising, through to its historic COVID-19 vaccine that changed global medicine. What’s next for Moderna beyond the pandemic? Tune in to explore how one biotech bet on mRNA and won. Whether you’re a biotech enth...

2 months ago

24 minutes

PETRI DISH PERSPECTIVES

Episode 20: Baxter

Send us a text Baxter may not always grab the biotech headlines, but its impact on modern healthcare is impossible to ignore. From the first commercially prepared IV solutions in the 1930s to pioneering dialysis fluids, blood systems, recombinant hemophilia therapies, and parenteral nutrition, Baxter has consistently solved medicine’s “unsexy but essential” problems. In this episode, we dive into the company’s origins, explore the backstories of its most important innovations, and trace how i...

2 months ago

23 minutes

PETRI DISH PERSPECTIVES

Episode 19: AstraZeneca

Send us a text In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead explores the remarkable journey of AstraZeneca, from its unlikely Swedish-British merger to blockbuster drugs like Nexium and Crestor, through near-decline, and ultimately its reinvention as a science-driven leader in oncology, cardiometabolic health, and global public health. Discover how bold leadership, high-risk bets, and groundbreaking discoveries like Tagrisso, Enhertu, and Farxiga transforme...

2 months ago

23 minutes

PETRI DISH PERSPECTIVES

Episode 18: Gilead

Send us a text In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the remarkable and controversial story of Gilead Sciences, a company that redefined what medicine could achieve. From its beginnings in the late 1980s under physician-scientist Michael Riordan, Gilead transformed antiviral drug development with breakthroughs in HIV treatment, revolutionized global health with a cure for hepatitis C, and pushed into oncology with cutting-edge CAR-T therapies. But alongsi...

2 months ago

24 minutes

PETRI DISH PERSPECTIVES

Episode 17: GSK

Send us a text In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the story of GlaxoSmithKline (GSK), one of the world’s most influential pharma giants! From scaling up penicillin production in WWII, to pioneering semi-synthetic antibiotics like amoxicillin, to leading the global vaccine race with Cervarix and Shingrix, GSK has left an indelible mark on modern medicine. We also explore its groundbreaking role in HIV treatment through ViiV Healthcare, and the blockbust...

3 months ago

24 minutes

PETRI DISH PERSPECTIVES

Episode 16: Amgen

Send us a text In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive deep into the origin story of Amgen, a company that helped turn “biotechnology” from a niche lab concept into a global medical force. We’ll trace Amgen’s unlikely beginnings in 1980, a time when gene splicing was still the stuff of scientific legend and meet the eclectic founding team: George Rathmann, the charismatic chemist-turned-executive; Winston Salser, the UCLA scientist eager to bring basic research ...

3 months ago

26 minutes

PETRI DISH PERSPECTIVES

Episode 15: BGI Genomics

Send us a text What happens when one of the world’s most powerful genomics companies rises from a college dorm in China and goes on to challenge the West’s biotech dominance? In this episode of Petri Dish Perspectives: Biotech Unleashed, we unravel the story of BGI Genomics, a company at the intersection of cutting-edge science, national ambition, and global controversy. From decoding the human genome to building the world’s largest sequencing fleet, BGI’s journey is as bold as it is complex....

3 months ago

23 minutes

PETRI DISH PERSPECTIVES

Episode 14: Abbott

Send us a text In this episode of Petri Dish Perspectives: Biotech Unleashed, host Manead takes you inside the remarkable story of Abbott Laboratories: a company that doesn’t chase headlines but touches billions of lives every day. From its origins in 1888 as a small Chicago pharmacy mixing precise plant-based pills, Abbott has grown into a global healthcare powerhouse behind life-changing products like the FreeStyle Libre glucose monitor, BinaxNOW COVID-19 tests, Similac baby formula, Ensure...

3 months ago

24 minutes

PETRI DISH PERSPECTIVES

Episode 13: Sarepta

Send us a text DISCLAIMER: This is a consistently changing situation. The episode was recorded approximately 4 PM EDT Monday, July 21, 2025. As of 7.40 PM EDT Monday, July 21, 2025 (Source: Sarepta), "Sarepta Therapeutics notified the U.S. FDA of its decision to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the United States, effective close of business Tuesday, July 22, 2025." 🎙️ When Hope Collides with Ris...

4 months ago

23 minutes

PETRI DISH PERSPECTIVES

Episode 12: Vertex

Send us a text 🔬✨ From Cystic Fibrosis Breakthroughs to Gene Editing Cures In this episode of Petri Dish Perspectives: Biotech Unleashed, Manead unpacks how Vertex turned cystic fibrosis from a fatal disease into a treatable condition and why they’re now tackling sickle cell, diabetes, and more with CRISPR and stem cell science. Discover how visionary chemists, Nobel-winning gene editors, and patient advocates built one of biotech’s most inspiring success stories, proving that deep science an...

4 months ago

24 minutes

PETRI DISH PERSPECTIVES

Episode 11: Genentech

Send us a text 🧬 From VC to Blockbusters: The Genentech Story In Episode 11 of Petri Dish Perspectives: Biotech Unleashed, host Manead dives into the legendary rise of Genentech, the startup that sparked the biotech revolution. From its humble beginnings in a borrowed lab to pioneering insulin, tPA, Herceptin, and more, learn how Genentech turned recombinant DNA into real-world cures. Discover the bold VC bets, game-changing antibodies, and the Roche acquisition that preserved its science-fi...

4 months ago

26 minutes